Gynecologic Cancers

Immunotherapy

Questions discussed in this category

In mismatch repair deficient recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why?

1 Answer available

Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?

1 Answer available

How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?

4 Answers available

What is your approach to immunotherapy-related pancreatitis?

How do you manage the initial event, including length of steroid taper and the role of pancreatic enzyme monitoring? What is your experience of subse...

1 Answer available

Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

3 Answers available

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

2 Answers available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

How do you choose 1st line therapy for recurrent cervical cancer?

Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...

1 Answer available

How do you determine which systemic therapy to recommend in the 2nd line setting for metastatic, PD-L1 NEGATIVE cervical cancer?

1 Answer available

Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?

Does the phase II KN-158 provide sufficient evidence to change management?

1 Answer available

Would you recommend 1st line pembrolizumab for PD-L1 positive recurrent/metastatic cervical cancer patient who is not a candidate for or refuses chemotherapy?

1 Answer available

When do you recommend PD-L1 testing for patients with recurrent cervical cancer?

Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?

1 Answer available

Papers discussed in this category

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Cancer management and research, 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Lancet Oncol., 2020 Mar 03

Risk of COVID-19 for patients with cancer.

Lancet, 2020 Feb 07

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Ann. Rheum. Dis., 2019 Sep 20

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

J Immunother Cancer, 2021 Feb

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

J Natl Compr Canc Netw,

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Ann Oncol,

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Immunother Cancer,

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer,

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

J Natl Compr Canc Netw,

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

J Clin Oncol, 2019 Nov 04

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

J Immunother Cancer, 2022 Jan

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

J Clin Oncol, 2022 Jan 06

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

Related Topics in Gynecologic Cancers